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INTRODUCTION
Colorectal cancer (CRC) is the second leading cause of can-
cer-related deaths in the U.S.A. and Europe (1). During the
last few years, many attempts have been made to define the
biological profile of CRC in order to improve early diagno-
sis and the prognostic stratification, and eventually find a
cure (2, 3). Although many biological factors have been impli-
cated in the development of CRC, a clinical relevance has not
yet been reached for most of them. 
Angiogenesis, the formation of a new blood vessel from
endothelial precursors, is a prerequisite for the development,
growth, and progression of solid malignancies (4). The vascu-
lar endothelial growth factor (VEGF) is one of the most potent
endothelial cell mitogens and plays a critical role in angio-
genesis. VEGF specifically binds to VEGF receptor tyrosine
kinase on endothelial cells to initiate intracellular signal trans-
duction pathways that mediate angiogenesis and vascular
permeability. In addition to stimulating angiogenesis, VEGF
may also have autocrine functions, acting as a survival factor
for tumor cells by protecting them from various forms of
stress and apoptosis (5-8).
The VEGF gene is located on chromosome 6p21.3 and
consists of eight exons that exhibit alternative splicing to form
a family of proteins (9, 10). Several polymorphisms have been
associated with variations in VEGF protein production and
reported to be involved in the development of several tumors
(11, 12) and autoimmune diseases (13, 14). Given these results,
it is also possible that a functional genetic variation in the
VEGF gene may contribute to the development and progres-
sion of CRC. However, there have been no studies in the lit-
erature that have investigated the single nucleotide poly-
morphisms (SNPs) of the VEGF gene and their relationship
to the susceptibility of CRC. Accordingly, the present study
examined 2 VEGF gene polymorphisms (-634G>C and
936C>T) previously reported to be related with VEGF pro-
duction, and evaluated the potential association of three
VEGF gene polymorphisms with the susceptibility and clini-
copathologic characteristics of CRC in the Korean popula-
tion. 
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Association of Vascular Endothelial Growth Factor Gene Polymorphisms
with Susceptibility and Clinicopathologic Characteristics of Colorectal
Cancer
Since vascular endothelial growth factor (VEGF) is known to be a potent pro-angio-
genic factor, we evaluated the potential association of two VEGF gene polymor-
phisms (-634G>C and 936C>T) with the susceptibility and the clinicopathologic
characteristics of colorectal cancer (CRC). The VEGF genotypes were determined
using fresh colorectal tissue from 465 patients who had undergone a surgical resec-
tion and peripheral blood lymphocytes from 413 healthy controls by PCR/DHPLC
assay. For the -634G>C polymorphism, the -634 GC or CC genotype was associ-
ated with a decreased risk of CRC (odds ratio [OR], 0.62; p=0.001) as a dominant
model of C allele, whereas the 936 TT genotype correlated with advanced stage/
metastasis, a high serum level of CA19-9, and an higher grade in patients with CRC.
In the haplotype analyses, haplotype -634C/936C and -634G/936T were associat-
ed with a decreased susceptibility of CRC (OR, 0.53 and 0.56; p<0.001, respec-
tively). These observations imply that the VEGF gene polymorphisms may be asso-
ciated with the susceptibility or clinicopathologic features of CRC. However, further
studies of other VEGF sequence variants and their biological functions are needed
to understand the role of the VEGF gene polymorphisms in the development and
progression of CRC.
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Study populations
All the tissues investigated in this study were obtained
from 465 native Korean patients with CRC who had under-
gone a surgical resection between January 2003 and August
2006 at Kyungpook National University Hospital (Daegu,
Korea). Based on a health-screening questionnaire, 413 unre-
lated, healthy Korean individuals without known medical
problems were also enrolled as the control group. The study
was approved by the Institutional Research Board of Kyung-
pook National University Hospital, and all individuals gave
written informed consent for study participation.
The diagnosis and staging of the colorectal adenocarcino-
ma were assessed according to the WHO classification (15)
and TNM classification set out by the American Joint Com-
mittee on Cancer (AJCC-UICC) (16).
Genotyping of VEGF gene polymorphisms
The extraction of genomic DNA from the peripheral blood
lymphocytes of the control group was performed using pro-
teinase-K digestion and phenol/chloroform extraction. For
the patient group, the genomic DNA was extracted from
fresh colorectal tumor tissue at the time of surgery using a
Wizard genomic DNA purification kit (Promega, Madison,
WI, U.S.A.). The VEGF -634G>C and 936C>T genotypes
were determined using a polymerase chain reaction/denatur-
ing high-performance liquid chromatography (PCR/DHPLC)
assay as described in the previous studies (17, 18). PCR pri-
mers were designed based on a Genbank reference sequence
(accession no. NT_007592). The PCR primers used for the
-634G>C and 936C>T polymorphisms were 5′ -CGACGGC-
TTGGGGAGATTGC-3′ (forward) and 5′ -GGGCGGTG-
TCTGTCTGTCTG-3′ (reverse); and 5′ -AGGGTTTCGG-
GAACCAGATC-3′ (forward) and 5′ -CTCGGTGATTTA-
GCAGCAAG-3′ (reverse), respectively. The PCR reactions
were performed in a 50- L reaction volume containing 50 ng
genomic DNA, 50 pM/L each primer, 10 mM/L dNTP, 5
×Q- solution, 10×PCR buffer (Tris-HCl , KCl, 15 mM/L
MgCl2, [NH2] 2SO4; pH8.7) and 2.5 units of HotStarTaq
polymerase (QIAGEN, Hilden, Germany). The PCR cycle
conditions consisted of an initial denaturation step at 94℃
for 15 min, followed by 40 cycles of 45 sec at 94℃, 45 sec
at 57℃, 45 sec at 72℃, and a final elongation at 72℃ for
10 min. The PCR products were denatured at 94℃ for 10
min, and hybridized for 45 min, and screened for a heterozy-
gous polymorphism based on a DHPLC analysis using a
gradient solution of 0.1 M TEAA (pH 7.0), 0.1 M TEAA,
25% acetonitrile, a washing solution with 8% acetonitrile
(syringe washing solution), and 75% acetonitrile (DNASep
�
Cartridge UltraClean and Storage Solution, Transgenomic,
Omaha, NE, U.S.A.), Column: alkylated nonporous poly
(styrene-divinylbenzene) DNASep
� Cartridge (Transgenomic,
Omaha, NE, U.S.A.), flow rate: 0.9 mL/min, oven tempera-
ture: 64℃, and UV: 260 nm. 
The remaining samples showing a single peak on the DH-
PLC were mixed with the PCR products of a known homozy-
gous genotype (homozygous A), and hybridized to run the
DHPLC again, as described above. Another type of homozy-
gous genotype (homozygous B) was confirmed when a dou-
ble peak appeared on the DHPLC. Several samples with three
different patterns on the DHPLC were directly sequenced
to reconfirm the accuracy of the DHPLC (Fig. 1).
Statistical analyses
The Hardy-Weinberg equilibrium for each polymorphism
was analyzed using the  2 test, which was also used to exam-
ine the statistical significance of the differences in the allele
frequency and genotype distribution between the groups.
The odds ratios (ORs) and 95% confidence intervals (CIs)
were obtained using an unconditional logistic regression anal-
ysis. For the patient group, the  2-test or ANOVA was used
to evaluate the relation between each polymorphism and
the tumor characteristics. The software PHASE (version
2.1), which uses a Bayesian statistical method, was used to
reconstruct the haplotypes for the VEGF gene (19). The p
value was generated using a 2-sided test. The analyses were
conducted using SPSS version 12.0 (SPSS, Chicago, IL, U.S.A.)
and SAS Genetic software (SAS Institute, Cary, NC, U.S.A.).
RESULTS
Patient characteristics
The clinical and pathologic characteristics of patients are
summarized in Table 1. The median age of the patients was
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Fig. 1. Algorithm for genotyping of VEGF gene polymorphisms
using a polymerase chain reaction/denaturing high-performance
liquid chromatography (PCR/DHPLC) assay.
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DHPLC analysis
DNA from tissue
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Mixed with known
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Double peak
hybridization
DHPLC analysis64 (range, 21-89) yr, and 248 patients (51.8%) were male.
There was no difference in age between the patient and con-
trol groups, while there was a male predominance in the con-
trol group. The pathologic stages after the surgical resection
were as follows: stage I (n=80, 17.2%), stage II (n=157, 33.8
%), stage III (n=157, 33.8%), and stage IV (n=71, 15.3%).
Genotype frequencies
The VEGF genotypes were successfully identified in all
878 enrolled subjects, and the frequencies of the genotypes
and alleles are listed in Table 2. The genotype distributions
of the two polymorphisms among the patients and controls
followed the Hardy-Weinberg equilibrium, and the frequen-
cies of the -634C and 936T alleles among the healthy Kore-
ans were 0.473 and 0.209, respectively. The incidence of each
genotype with the -634G>C polymorphism differed between
the two groups (p=0.001), where the combined GC and CC
genotype was significantly associated with a decreased risk
of CRC (OR, 0.62; 95% CI, 0.47-0.83; p=0.001) compared
with the GG genotype as the dominant model for the C
allele. For the 936C>T polymorphism, there was no differ-
ence in the genotype or allele distribution between the patient
and control groups (p=0.64 and 0.71, respectively).
Association of genotypes with clinicopathologic features
For the patient group, the TT genotype of 936C>T poly-
morphism was significantly associated with advanced stage
(OR, 3.83; 95% CI, 1.22-12.03; p=0.02), distant metasta-
sis (OR, 8.38; 95% CI, 3.00-23.51; p<0.001), high serum
level of CA19-9 (OR, 2.96; 95% CI, 1.04-8.40; p=0.04), and
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Characteristics Characteristics Patients (n=465) Controls (n=413)
Age, median (range) 64 (21-89) 61 (34-86)
Sex (%)
Male 241 (51.8) 333 (80.6)
Female 224 (48.2) 80 (19.4)
Location of primary tumor (%)
Colon cancer 264 (56.7)
Rectal cancer 201 (43.3)
Stage (%)
I 80 (17.2)
II 157 (33.8)
III 157 (33.8)
IV 71 (15.3)
Tumor marker (%)*
CEA, elevated 117 (25.3)
CA19-9, elevated 79 (17.1)
Differentiation (%)
Well 67 (14.4)
Moderate 357 (76.9)
Poor 21 (4.5)
Mucinous 18 (3.9)
Signet ring cell 2 (0.4)
Table 1. Characteristics of patients with colorectal cancer and
controls
*, tested in 462 patients. CEA, carcinoembryonic antigen.
Polymorphism Total (n=878) Patient (n=465) Control (n=413) p value Odds ratio (95% CI)
-634G>C
Genotype  <0.001*
GG 272 (31.0) 166 (35.7) 106 (25.7) Reference
GC 416 (47.4) 193 (41.5) 223 (54.0) <0.001 0.55 (0.41-0.75)
CC 190 (21.6) 106 (22.8) 84 (20.3) 0.26 0.81 (0.55-1.18)
Dominant model of C allele
GG 272 (31.0) 166 (35.7) 106 (25.7) Reference
GC+CC 606 (69.0) 299 (64.3) 307 (74.3) 0.001 0.62 (0.47-0.83)
Allele
G 960 (54.7) 525 (56.5) 435 (52.7) Reference
C 796 (45.3) 405 (43.5) 391 (47.3) 0.11 0.86 (0.71-1.04)
936C>T
Genotype 0.64*
CC 545 (62.1) 293 (63.0) 252 (61.0) Reference
CT 305 (34.7) 156 (33.5) 149 (36.1) 0.43 0.89 (0.67-1.18)
TT 28 (3.2) 16 (3.4) 12 (2.9) 0.84 1.19 (0.50-2.35)
Dominant model of T allele
CC 545 (62.1) 293 (63.0) 252 (61.0) Reference
CT+TT 333 (37.9) 172 (37.0) 161 (39.0) 0.54 0.92 (0.70-1.21)
Allele
C  1,395 (79.4) 742 (79.8) 653 (79.1) Reference
T 361 (20.6) 188 (20.2) 173 (20.9) 0.71 0.96 (0.76-1.21)
Table 2. Genotype distributions (%) and allele frequencies in patients with colorectal cancer and controls
*, p value was estimated using 
2-test for distribution of three genotypes.
CI, confidence interval.higher grade (p=0.002). However, no association of -634G>
C polymorphism with clinicopathologic features was observ-
ed (Table 3, 4).
Haplotype analyses 
The VEGF -634G>C and 936C>T polymorphisms exhib-
ited an intermediate linkage disequilibrium (D′ =0.50), and
Table 5 shows the frequencies and ORs of the 4 reconstruct-
ed haplotypes for the two polymorphisms of the VEGF
gene, as predicted by a Bayesian algorithm. Haplotype GC
was the most frequent type in the patient group (41.5%),
whereas haplotype CC was most frequent in the control
group (43.1%). When compared with wild type (GC), the
haplotype CC (OR, 0.53; 95% CI, 0.43-0.66; p<0.001) and
GT (OR, 0.56; 95% CI, 0.42-0.74; p<0.001) were signifi-
cantly associated with a decreased susceptibility of CRC.
However, no significant associations were observed between
any of the haplotypes and the clinical features of CRC (data
not shown). 
DISCUSSION
The present study investigated the potential impact of 2
VEGF gene polymorphisms on the susceptibility and clini-
copathologic features of colorectal adenocarcinoma in quite
a large population of Korean patients. As a result, the fre-
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-634G>C
GG GC CC
936C>T
CC CT TT
Sex 
Male 86 99 56 152 77 12
Female 79 94 51 140 79 5
p value 0.92 0.88 0.59 0.15
OR (95% CI) 1 1.02 (0.67-1.55) 0.96 (0.59-1.57) 1 1.11 (0.76-1.64) 0.45 (0.16-1.32)
Age (yr)
≤60 65 74 42 121 56 4
>60 100 119 65 171 100 13
p value 0.80 0.90 0.25 0.15
OR (95% CI) 1 1.06 (0.69-1.62) 1.03 (0.63-1.70) 1 1.26 (0.85-1.89) 2.30 (0.73-7.22)
CEA*
Normal 125 146 74 224 110 11
Elevated 39 47 31 65 46 6
p value 0.90 0.30 0.11 0.23
OR (95% CI) 1 1.03 (0.63-1.68) 1.34 (0.77-2.33) 1 1.44 (0.93-2.24) 1.88 (0.67-5.28)
CA19-9*
Normal 135 160 88 244 128 11
Elevated 29 33 17 45 28 6
p value 0.88 0.75 0.52 0.04
OR (95% CI) 1 0.96 (0.56-1.66) 0.90 (0.47-1.73) 1 1.19 (0.71-1.99) 2.96 (1.04-8.40)
Stage
I+II 74 111 52 159 74 4
III+IV 92 81 55 134 81 13
p value 0.009 0.40 0.20 0.02
OR (95% CI) 1 0.57 (0.36-0.87) 0.81 (0.50-1.32) 1 1.29 (0.87-1.91) 3.83 (1.22-12.03)
LN involvement
Negative 76 117 59 165 81 6
Positive 87 75 49 127 73 11
p value 0.007 0.20 0.43 0.10
OR (95% CI) 1 0.56 (0.37-0.86) 0.73 (0.45-1.18) 1 1.17 (0.79-1.73) 2.38 (0.86-6.61)
Distant metastasis
Negative 137 173 85 265 121 9
Positive 28 19 23 28 34 8
p value 0.05 0.38 <0.001 <0.001
OR (95% CI) 1 0.55 (0.29-1.00) 1.31 (0.71-2.43) 1 2.65 (1.54-4.57) 8.38 (3.00-23.45)
Table 3. Association of VEGF gene polymorphisms with clinical characteristics in patients with colorectal cancer (n=465)
*, tested in 462 patients.
VEGF, vascular endothelial growth factor; OR, odds ratio; CI, confidence interval; LN, lymph node; CEA, carcinoembryonic antigen.quencies of -634C and 936T alleles were 0.473 and 0.209,
respectively, which differ from those of Japanese (0.353 and
0.150, respectively) as well as those of Caucasians (0.335 and
0.150, respectively) (20, 21). Moreover, it was observed that
the combined GC and CC genotypes of the -634G>C poly-
morphism, and haplotype -634C/936C and -634G/936T
were associated with a decreased susceptibility, while 936
TT genotype with an adverse clinicopathologic feature of
CRC. Given the homogenous ethnic background of the Kore-
an patients, any potential confounding effect due to ethnici-
ty is likely to be small in the present study. However, these
results might be caused by somatic alteration in the process
of colorectal carcinogenesis because tumor tissue was used
for DNA source of the patient group in the present study,
although data on the difference between germline and somat-
ic SNPs of VEGF gene have not been reported. Furthermore,
the effect of the VEGF gene polymorphisms on the suscep-
tibility of CRC may be due to linkage disequilibrium with
other functional variants in the VEGF gene or other cytokine
gene (22, 23). 
Since VEGF or its family plays a critical role in tumor-relat-
ed angiogenesis, several functional polymorphisms in the
VEGF gene have already been reported to be associated with
a VEGF gene expression or an increased risk of solid tumors
(11, 12, 23, 24), making them potential predictive markers
for clinical outcomes (22-24). For example, the -634C and
936T alleles as a dominant model or CGT haplotype (-1498T
>C, -634G>C, and 936C>T) among the VEGF gene poly-
morphisms have been associated with a significantly decreas-
ed risk of small cell lung cancer (SCLC), while the TCC hap-
lotype conferred a significantly increased risk of SCLC in a
previous study by the present authors (25). Plus, a strong
association between the -634 CC or 936 TT genotypes and
a larger tumor size was observed, while the -634 CC geno-
types was strongly correlated with poor differentiation and
advanced stage of disease in gastric cancer (24).
One possible explanation for these results is that the DNA
sequence variations in the VEGF gene may alter VEGF pro-
duction and/or activity, thereby causing inter-individual dif-
ferences in the development and progression of tumors. A
few studies have already reported that VEGF gene polymor-
phisms are associated with VEGF production, yet the results
are inconsistent. Awata et al. (26) reported an association
between the -634 CC genotype and a higher serum VEGF
concentration in the normal Japanese population. Koukou-
rakis et al. (27) also reported that genetic polymorphisms
including the -634 region were correlated with VEGF pro-
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-634G>C
GG GC CC
936C>T
CC CT TT
Histolotic grade (n=444)
Grade 1 21 27 18 42 24 0
Grade 2 125 150 82 228 118 11
Grade 3 9 7 5 11 6 4
p value 0.70 0.71 0.96 0.002
Lymphatic invasion (n=464)
Negative 70 75 44 119 62 8
Positive 93 118 64 173 93 9
p value 0.46 0.72 0.88 0.61
OR (95% CI) 1 1.18 (0.78-1.81) 1.10 (0.67-1.79) 1 1.03 (0.29-1.54) 0.77 (0.29-2.06)
Vascular invasion (n=463)
Negative 154 184 103 279 145 17
Positive 9 8 5 12 10 0
p value 0.55 0.75 0.28 1.00
OR (95% CI) 1 0.74 (0.28-1.98) 0.83 (0.27-2.55) 1 1.60 (0.68-3.80) -
Neural invasion (n=464)
Negative 97 106 54 172 78 7
Positive 66 87 54 120 77 10
p value 0.38 0.12 0.08 0.16
OR (95% CI) 1 1.21 (0.79-1.84) 1.47 (0.90-2.40) 1 1.42 (0.96-2.09) 2.05 (0.76-5.53)
Table 4. Association of VEGF gene polymorphisms with pathologic characteristics in patients with colorectal cancer
VEGF, vascular endothelial growth factor; OR, odds ratio; CI, confidence interval; LN, lymph node.
VEGF, vascular endothelial growth factor; CI, confidence interval.
-634G>C/
936C>T
haplotype
Patient
(%)
Control
(%)
p value
Odds ratio
(95% CI)
GC 454 (41.5) 297 (36.0) 1 (Reference)
GT 117 (14.4) 138 (16.7) <0.001 0.56 (0.42-0.74)
CC 288 (38.3) 356 (43.1) <0.001 0.53 (0.43-0.66)
CT 71 (5.9) 35 (4.2) 0.20 1.20 (0.86-2.04)
Table 5. Distribution of VEGF haplotypes predicted by Bayesian
algorithm in patients with colorectal cancer and controlstein expression in cancer cells and angiogenesis in tumor tis-
sue. Renner et al. (28) demonstrated that VEGF plasma lev-
els were significantly lower in carriers of the 936T allele,
whereas Krippl et al. (23) reported that the 936T allele was
associated with a lower VEGF plasma level and decreased
risk of breast cancer (OR, 0.51; 95% CI, 0.38-0.70). Mean-
while, Watson et al. (10) documented that the GG genotype
for the -634G>C polymorphism was significantly correlat-
ed with higher VEGF production from stimulated periph-
eral blood mononuclear cells. Stevens et al. (29) also report-
ed that haplotype -460C/+405G had a higher promoter
activity than haplotype -460T/+405C. 
In summary, the -634G>C and 936C>T polymorphisms
in the VEGF gene was found to be associated with suscepti-
bility or adverse clinicopathologic features of CRC in the cur-
rent study. However, further studies of other VEGF sequence
variants and their biological functions are needed to under-
stand the role of the VEGF polymorphisms and haplotypes
in the development and progression of CRC. Moreover, since
genetic polymorphisms often vary between ethnic groups,
more studies are also warranted to clarify the association bet-
ween the VEGF polymorphisms and CRC in diverse ethnic
populations.
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